Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Incyte Corporation INCY

Healthcare Biotechnology
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia... see more

Recent & Breaking News (NDAQ:INCY)

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis

Business Wire 2 days ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire 2 days ago

Incyte Announces FDA Approval of Jakafi XR(TM) (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

Business Wire 7 days ago

Incyte to Present at Upcoming Investor Conferences

Business Wire 10 days ago

Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer

Business Wire 11 days ago

Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates

Business Wire 11 days ago

Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Business Wire April 21, 2026

Incyte to Report First Quarter Financial Results

Business Wire April 9, 2026

Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

GlobeNewswire April 7, 2026

Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)

GlobeNewswire April 2, 2026

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Business Wire March 28, 2026

Incyte Announces Executive Leadership Appointments

Business Wire March 25, 2026

Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Business Wire March 20, 2026

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico

GlobeNewswire March 17, 2026

Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil

GlobeNewswire March 17, 2026

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)

Business Wire March 6, 2026

Incyte to Present at Upcoming Investor Conferences

Business Wire February 17, 2026

Incyte Reports Fourth Quarter and Full Year 2025 Financial Results

Business Wire February 10, 2026

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)

Business Wire January 30, 2026

Incyte to Report Fourth Quarter and Year-End 2025 Financial Results

Business Wire January 27, 2026

Podcasts